Galinier M, Senard J M, Valet P, Doazan J P, Durrieu G, Tran M A, Monstastruc J L, Bounhoure J P
Department of Cardiology, Rangueil Hospital, Toulouse, France.
Clin Exp Hypertens. 1994 May;16(3):373-89. doi: 10.3109/10641969409072223.
To investigate the influence of blood pressure disturbances on human platelet alpha 2-adrenoceptor density, we studied 7 normotensive Parkinsonians with orthostatic hypotension and 23 mild essential hypertensive patients. Plasma catecholamine levels were measured by HPLC and alpha 2-adrenoceptor number and affinity determined by [3H]-yohimbine binding. Alpha-adrenergic reactivity was investigated by blood pressure response to noradrenaline infusion in Parkinsonians and by adrenaline-induced platelet aggregation in hypertensive patients. In Parkinsonians with orthostatic hypotension, in comparison with Parkinsonians without orthostatic hypotension and normotensive control subjects age and sex matched, noradrenaline plasma levels were significantly lower (62 +/- 11, 195 +/- 14 and 219 +/- 13 pg. ml-1 respectively, p < 0.05), platelet alpha 2-adrenoceptor number was significantly higher (313 +/- 52, 168 +/- 9 and 174 +/- 4 fmol.mg-1 protein respectively, p < 0.05) and the noradrenaline dose required for a 25 mm Hg increase of systolic blood pressure significantly lower (0.19 +/- 0.03, 0.86 +/- 0.11 and 0.68 +/- 0.10 microgram.Kg-1 respectively, p < 0.05). In hypertensive patients, in comparison with normotensive control subjects age and sex matched, plasma noradrenaline levels remained unchanged (306 +/- 68 vs 246 +/- 28 pg.ml-1) whereas both platelet alpha 2-adrenoceptor number (137 +/- 15 vs 177 +/- 15 fmol.mg-1 protein, p < 0.05) and velocity of adrenaline-induced platelet aggregation were significantly decreased. These results indicate that platelet alpha 2-adrenoceptor density is related to blood pressure values. In Parkinsonians with orthostatic hypotension, the up-regulation of alpha 2-adrenoceptors was induced by the decrease of endogenous catecholamines. In contrast, in essential hypertension a down-regulation of alpha 2-adrenoceptors was observed in spite of no significant increase of catecholamine levels. These results suggest that only sustained abnormal plasma noradrenaline levels could allow the development of alpha 2-adrenoceptor regulatory mechanisms.
为研究血压紊乱对人血小板α2 - 肾上腺素能受体密度的影响,我们对7名患有体位性低血压的血压正常帕金森病患者和23名轻度原发性高血压患者进行了研究。通过高效液相色谱法测定血浆儿茶酚胺水平,并用[3H] - 育亨宾结合法测定α2 - 肾上腺素能受体数量和亲和力。通过帕金森病患者对去甲肾上腺素输注的血压反应以及高血压患者肾上腺素诱导的血小板聚集来研究α - 肾上腺素能反应性。在患有体位性低血压的帕金森病患者中,与无体位性低血压的帕金森病患者以及年龄和性别匹配的血压正常对照受试者相比,血浆去甲肾上腺素水平显著降低(分别为62±11、195±14和219±13 pg/ml,p < 0.05),血小板α2 - 肾上腺素能受体数量显著升高(分别为313±52、168±9和174±4 fmol/mg蛋白质,p < 0.05),使收缩压升高25 mmHg所需的去甲肾上腺素剂量显著降低(分别为0.19±0.03、0.86±0.11和0.68±0.10 μg/kg,p < 0.05)。在高血压患者中,与年龄和性别匹配的血压正常对照受试者相比,血浆去甲肾上腺素水平保持不变(306±68 vs 246±28 pg/ml),而血小板α2 - 肾上腺素能受体数量(137±15 vs 177±15 fmol/mg蛋白质,p < 0.05)和肾上腺素诱导的血小板聚集速度均显著降低。这些结果表明血小板α2 - 肾上腺素能受体密度与血压值相关。在患有体位性低血压的帕金森病患者中,α2 - 肾上腺素能受体的上调是由内源性儿茶酚胺的减少引起的。相反,在原发性高血压中,尽管儿茶酚胺水平没有显著升高,但观察到α2 - 肾上腺素能受体的下调。这些结果表明,只有持续异常的血浆去甲肾上腺素水平才能促使α2 - 肾上腺素能受体调节机制的发展。